{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:08:19Z","timestamp":1792613299279,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107160","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:37:51Z","timestamp":1774283871000},"page":"107160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup"],"prefix":"10.1016","volume":"109","author":[{"given":"Gerard T","family":"Harty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saipriya","family":"J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikalp","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2026.107160_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener. Dis. Manage"},{"issue":"8","key":"10.1016\/j.msard.2026.107160_bib0026","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","volume":"35","author":"Berardi","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"12 Suppl 6","key":"10.1016\/j.msard.2026.107160_bib0011","first-page":"S33","article-title":"Identifying and treating patients with suboptimal responses","volume":"63","author":"Cohen","year":"2004","journal-title":"Neurology."},{"issue":"17","key":"10.1016\/j.msard.2026.107160_bib0031","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2026.107160_bib0008","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1185\/03007995.2015.1067191","article-title":"Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis","volume":"31","author":"Derfuss","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.msard.2026.107160_bib0009","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","article-title":"Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","volume":"11","author":"Devonshire","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107160_bib0028","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE decision support unit technical support documents. heterogeneity: subgroups, meta-regression, bias and bias-adjustment. London: National Institute for Health and Care Excellence (NICE) unless otherwise stated. All rights reserved; 2012."},{"issue":"9316","key":"10.1016\/j.msard.2026.107160_bib0029","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107160_bib0013","unstructured":"European Medicines Agency. EPAR summary for the public. Mavenclad. London, UK. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB document_library\/EPAR_Summary_for_the_publichuman\/004230WC500234564.pdf [Last accessed 5 May 2024]."},{"key":"10.1016\/j.msard.2026.107160_bib0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.msard.2017.07.003","article-title":"Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?","volume":"17","author":"Fern\u00e1ndez","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107160_bib0030","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","volume":"6","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2026.107160_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107160_bib0014","unstructured":"Food and Drug Administration. Mavenclad. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022561Orig1s000Approv.pdf [Last accessed 5 May 2024]."},{"issue":"10","key":"10.1016\/j.msard.2026.107160_bib0012","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1185\/03007990903158364","article-title":"Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command","volume":"25","author":"Freedman","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.msard.2026.107160_bib0016","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107160_bib0017","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2026.107160_bib0033","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jval.2018.11.015","article-title":"Impact of nonrandomized dropout on treatment switching adjustment in the relapsing-remitting multiple sclerosis CLARITY trial and the CLARITY extension study","volume":"22","author":"Gorrod","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2026.107160_bib0025","doi-asserted-by":"crossref","unstructured":"Harty GT, Jones M, Maheshwari V, Saipriya J. Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis. under review. 2025;.","DOI":"10.1016\/j.msard.2026.107214"},{"issue":"3","key":"10.1016\/j.msard.2026.107160_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013430","article-title":"Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis","volume":"7","author":"Huisman","year":"2017","journal-title":"BMJ Open."},{"issue":"3","key":"10.1016\/j.msard.2026.107160_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107160_bib0019","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1177\/1352458518771846","article-title":"Comparisons of therapies in different scenarios help complete the puzzle","volume":"24","author":"Kalincik","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2026.107160_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107160_bib0001","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.msard.2026.107160_bib0002","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00702-013-1079-9","article-title":"Is MS an inflammatory or primary degenerative disease?","volume":"120","author":"Losy","year":"2013","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"3","key":"10.1016\/j.msard.2026.107160_bib0003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology."},{"issue":"10","key":"10.1016\/j.msard.2026.107160_bib0022","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40263-016-0377-9","article-title":"Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the number needed to treat to Benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): A systematic review and meta-analysis","volume":"30","author":"Mendes","year":"2016","journal-title":"CNS. Drugs"},{"issue":"11","key":"10.1016\/j.msard.2026.107160_bib0005","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/jnnp-2013-304951","article-title":"Characterising aggressive multiple sclerosis","volume":"84","author":"Menon","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2026.107160_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS. Med."},{"issue":"7","key":"10.1016\/j.msard.2026.107160_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2015.85","article-title":"Aggressive multiple sclerosis: proposed definition and treatment algorithm","volume":"11","author":"Rush","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107160_bib0024","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2026.107160_bib0032","article-title":"Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: real-world evidence from MSBase","volume":"10","author":"Spelman","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10130","key":"10.1016\/j.msard.2026.107160_bib0004","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.msard.2026.107160_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127960","article-title":"A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis","volume":"10","author":"Tolley","year":"2015","journal-title":"PLoS. One"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:19:04Z","timestamp":1781525944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"alternative-id":["S2211034826001963"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107160","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107160"}}